Abbott Laboratories will file in Europe and the US next year to designate its Humira biotherapeutic for treatment of psoriasis after clinical trial results show patients responded twice as well to ...

Please provide your email address to receive an email when new articles are posted on . The complete response letter cites facility issues in denying the biosimilar. The approval process had been on ...

The FDA has accepted the supplemental biologics license application for interchangeability designation for Hadlima (adalimumab-bwwd), a biosimilar to Humira, from Organon (NYSE:OGN) and Samsung ...

Teva’s dream of a smooth summer launch for its Alvotech-partnered Humira biosimilar is in jeopardy after its Icelandic compatriot weathered a second FDA snub in less than a year. Manufacturing ...

INCHEON, South Korea and JERSEY CITY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today announced that the U.S. Food and Drug Administration (FDA) ...

Adalimumab-bwwd (Hadlima; Samsung Bioepis Co., Ltd. and Organon & Co.) is seeking to become the third Humira biosimilar deemed interchangeable with the reference product. The FDA has accepted a ...

Shire has terminated a five-year-old collaboration with Momenta Pharmaceuticals to develop and commercialize a proposed biosimilar of Humira (adalimumab). Momenta said in a statement Shire terminated ...

Amgen to work with Daiichi Sankyo on 9 biosimilars in Japan U.S. FDA accepts Samsung Bioepis infliximab biosim for review Samsung Bioepis aims at AbbVie Humira patents in U.K. lawsuit AbbVie hangs ...

Medicare Part D may cover Humira when a person can self-administer it at home. A person’s Part D costs for Humira will depend on the plan’s formulary and their specific plan. Similarly, Medicare ...